Trastuzumab Monoclonal Antibody Derived From Mouse
Human IgG Mouse Monoclonal Antibody |
|
E10G20464 |
EnoGene |
100 μl |
EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
Human IgG antibody Laboratories manufactures the trastuzumab monoclonal antibody derived from mouse reagents distributed by Genprice. The Trastuzumab Monoclonal Antibody Derived From Mouse reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact mouse Antibody. Other Trastuzumab products are available in stock. Specificity: Trastuzumab Category: Monoclonal Group: Antibody Derived
Mouse anti-human IgG monoclonal antibody |
|
MyBiosource |
1mg |
EUR 265 |
Mouse anti-human IgG monoclonal antibody |
|
MyBiosource |
5x1mg |
EUR 1035 |
Human IgG Monoclonal Antibody |
|
UpingBio |
100 ul |
EUR 200 |
Fluorescent labeled exosome derived from MSC from human adipose tissue |
|
Creative BioMart |
Each |
EUR 1593.75 |
|
Description: Exosome |
Fluorescent labeled exosome derived from MSC from human adipose tissue |
|
Creative BioMart |
Each |
EUR 1249.5 |
|
Description: Exosome |
Antibody Derived information
Trastuzumab deruxtecan |
|
HY-138298A |
MedChemExpress |
1 mg |
EUR 2326.88 |
|
Description: Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer[1][2]. |
Trastuzumab deruxtecan |
|
MBS5797737-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
Trastuzumab deruxtecan |
|
T36646-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
|
|
Description: Trastuzumab deruxtecan |
Trastuzumab deruxtecan |
|
T36646-1g |
TargetMol Chemicals |
1g |
Ask for price |
|
|
|
Description: Trastuzumab deruxtecan |
Trastuzumab deruxtecan |
|
T36646-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
|
|
Description: Trastuzumab deruxtecan |
Trastuzumab deruxtecan |
|
T36646-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
|
|
Description: Trastuzumab deruxtecan |
Trastuzumab deruxtecan |
|
T36646-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
|
|
Description: Trastuzumab deruxtecan |
Anti-HER2 (Trastuzumab), humanized Antibody |
|
A1046-100 |
Biovision |
each |
EUR 601.2 |
Trastuzumab deruxtecan (Enhertu) |
|
JH913995 |
J&H Chemical |
1 Each |
Ask for price |
Anti-HER2 [Trastuzumab] |
|
E2209948 |
EnoGene |
1mg |
Ask for price |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
Trastuzumab deruxtecan (solution) |
|
HY-138298 |
MedChemExpress |
1 mg (10 mg/mL * 100 μL in Aqueous solution) |
EUR 2164.54 |
|
Description: Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer[1][2]. |
Trastuzumab emtansine |
|
MBS5797738-10mg |
MyBiosource |
10mg |
EUR 2170 |
Trastuzumab emtansine |
|
MBS5797738-5mg |
MyBiosource |
5(mg |
EUR 1360 |
Trastuzumab emtansine |
|
MBS5797738-5x10mg |
MyBiosource |
5x10(mg |
EUR 9605 |
Trastuzumab emtansine |
|
T36647-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
|
|
Description: Trastuzumab emtansine |
Trastuzumab emtansine |
|
T36647-1g |
TargetMol Chemicals |
1g |
Ask for price |
|
|
|
Description: Trastuzumab emtansine |